The incidence of candidemia has increased in recent years. This paper reports a retrospective analysis of 270 cases of candidemia occurring from January 2000 to December 2009 at a teaching hospital in China. Demographic and clinical data were collected from patient medical records and the hospital's laboratory database. Candida albicans (35.9z) was the most prevalent species isolated, followed by C. tropicalis (21.8z) and C. glabrata (13.0z). Antifungal susceptibilities to fluconazole, flucytosine, and amphotericin B tended to decline over the study period. The most common risk factors were the presence of central venous catheters, endotracheal intubation, hypoproteinemia, renal failure, and concurrent bacteremia. In the 181 (67.0z) patients who died during hospitalization, endotracheal intubation, hypoproteinemia, and C. albicans were the major factors associated with mortality. This study highlights the importance of considering the possibility of invasive Candida infection in patients exposed to these risk factors.
INTRODUCTION
Nosocomial bloodstream infections are an important cause of morbidity and mortality in hospitalized patients (1) . Approximately 7.6-9.0z of nosocomial bloodstream infections are due to Candida spp., and in the United States, this is the fourth most common cause of morbidity and mortality in hospitalized patients (2) (3) (4) . These problems are particularly serious for patients with invasive medical devices. In addition, the incidence of such infections has increased with the use of immunosuppressive regimens, broad-spectrum antimicrobial agents, and aggressive chemotherapy (5) (6) (7) . Although Candidia albicans has long been the most common isolate obtained from the blood of patients with invasive fungal infection (IFI), several studies have demonstrated an increased prevalence of other Candida spp. such as C. glabrata and C. krusei (6, 8, 9) . Given the formation of candidal biofilms on the surfaces of indwelling devices and an increasing secondary resistance to azole antifungal agents (10) (11) (12) , these yeasts present a therapeutic challenge.
Although many medical interventions and novel antifungal drugs have been developed, morbidity and mortality rates due to candidemia have hardly improved over the past 20 years (13, 14) . It is thus necessary to investigate the epidemiology of candidemia in modern China. In the present retrospective survey, we reviewed the records of patients who were treated at the Southwest Hospital of the Third Military Medical University of China from 2000 to 2009. This study may provide further insight into the epidemiology of candidemia.
METHODS

Study design:
We conducted a retrospective study (from January 1, 2000 to December 31, 2009 ) to examine the prevalence of Candida spp. in blood cultures and to investigate risk factors associated with candidemia at the Southwest Hospital (approximately 2,000 beds) of the Third Military Medical University, Chongqing, China. An episode of candidemia was defined as at least one positive blood culture of Candida during a single hospitalization. The candidemia infection rate was defined as the percentage of candidemia patients divided by all admitted patients. The hospital's ethics committee approved the study protocol in accordance with code 201128.
Organism identification: Candida spp. were isolated from positive blood culture bottles (BacT/Alert 3D 240; bioM áerieux, Marcy l' ÁEtoile, France) by subculturing separately on Sabouraud dextrose agar and chocolate agar plates, both containing antibiotics. The presence of Candida was verified using microscopic (germ tube formation in horse serum) and biochemical (API20 C AUX and/or ATB ID 32C; bioM áerieux) assays.
Susceptibility testing: The susceptibility to antifungal drugs (fluconazole, flucytosine, and amphotericin B) of 270 Candida strains was tested in vitro using a commercial agar diffusion assay kit (A/S Rosco, Taastrup, Denmark). The Rosco Neo-Sensitabs tablet diffusion assay was performed in accordance with the manufacturer's instructions (15, 16) . Breakpoints for the antifungal agents were interpreted as the manufacturer's definitions; isolates with a fluconazole zone diameter of AE22 : Hypoproteinemia was defined when the patients had lower plasma total protein º60 g/L or albumin º35 g/L. 4) : Neutrophils: ages º10 years, º1.5 × 10 9 /L; 10-18 years, º1.8 × 10 9 /L; adults º2 × 10 9 /L; albumin º35 g/L; total lymphocyte count º1.5 × 10 9 /L. 5) : Acute renal failure (sudden and often temporary loss of kidney function with nitrogen waste retention and hypourocrinia) or chronic renal failure (slow progressive loss of kidney function over a span of years, resulting in permanent kidney failure). 6) : Exposure to AE3 antibiotics. LOS, length of hospital stay; CVC, central venous catheter. 511 mm were classified as susceptible. Susceptibility to amphotericin B and flucytosine was verified when the isolates exhibited zone diameters of AE15 mm and AE20 mm, respectively. Our laboratory followed the manufacturer's recommendation that, for the purposes of quality control, C. glabrata, Candida guilliermondii, Cryptococcus humicolus, and C. krusei should be considered one group: Candida spp. (17, 18) . The quality control strains were ATCC 90028, ATCC 22019, and ATCC 6258.
Variables: Records were reviewed for demographic data (age, sex, and disease history), and anticipated potential risk factors, including parenteral nutrition, mechanical ventilation, immunosuppression, use of central venous catheters (CVCs; including peripherally inserted, tunneled and non-tunneled, and arterial lines), antifungal prophylaxis, surgery within 30 days prior to diagnosis, and prior glucocorticosteroid and immunodepressant use. Glucocorticosteroid use was defined as the administration of AE10 mg/day prednisolone or the equivalent dose of an alternative corticosteroid. Administration agents such as tacrolimus, cyclosporine, and mycophenolate mofetil were considered immunodepressives. Furthermore, neutropenia (absolute neutrophil count of Ã500 cells/mm 3 ), the use of antibiotic(s) within 7 days prior to diagnosis, and concomitant bacterial infections (culture-confirmed) were also considered potential risk factors.
Statistical analysis: Categorical data were analyzed using the chi-square (x 2 ) test. Clinical factors significantly associated with death (Table 1) were entered as independent variables in a multiple regression model to identify mortality predictors after adjustment for possible comorbidities (concurrent bacteremia, hypoproteinemia, and renal failure) and therapeutic factors (presence of CVC, endotracheal intubation, and total parenteral nutrition). As no significant difference in mortality was found among the non-albicans Candida spp. subgroups, we combined them as one group to fit the regression model. P-values º 0.05 (2-tailed) were considered statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences (version 10.0; SPSS, Chicago, Ill., USA). Results are presented as the mean or median with range or standard deviation, or as a percentage, as appropriate. 2000  6  3  1  0  3  13  2001  7  4  2  1  3  17  2002  7  4  2  2  5  20  2003  6  5  0  3  9  23  2004  11  6  2  0  5  24  2005  12  7  4  3  7  33  2006  12  9  2  2  8  33  2007  11  8  5  2  7  33  2008  13  5  10  2  4  34  2009  12  8  7  6  7  40   Total  97  59  35  21  58  270 1) : C. famata, C. guilliermondii, C. krusei, C. lipolytica, C. lusitaniae, C. pulcherrima, and C. utilis. 
RESULTS
We identified 270 cases of candidemia retrospectively for the study period (January 2000 to December 2009). Patients had a median age of 63 years (range, 1-92 years) ( Table 1 ). All were nosocomial infections. Comorbidities, which included renal failure, malignancy, and possible aggressive chemotherapy-related hypoproteinemia, as well as therapy-associated factors such as broad-spectrum antimicrobial agents, endotracheal intubation, parenteral nutrition, and the presence of CVCs, were significant risk factors for development of candidemia ( Table 1) .
The median length of hospital stay (LOS) prior to candidemia was 15 Table 1 . Patients with candidemia caused by C. albicans were more likely to die than those with infections caused by other species were; however, no significant differences in mortality were found among the non-albicans Candida spp.
The candidemia infection rate refers to the number of candidemia patients divided by the total number of admitted patients during the 10-year study period. Over this decade, the annual candidemia infection rate was relatively stable, although the total number of candidemia cases increased slightly. The candidemia infection rate was 4.77 ± 0.42 × 10 -6
. Table 2 lists the numbers of candidemia cases by causal species throughout the study period. There was no significant change in the rank order of the top causal species except for C. glabrata in 2008 and C. parapsilosis in 2009. C. albicans was the species isolated in the majority of the candidemia cases; however, cases from which other Candida spp. were isolated also increased. In contrast to previous reports (19, 20) , the prevalence of C. albicans detected in the present study was 30-45z, except in 2003. Table 3 From 2000 to 2009, the mortality rates due to C. albicans, C. tropicalis, C. glabrata, and other Candida spp. infections were 77.3z (75/97), 52.5z (31/59), 68.6z (24/35), and 64.6z (51/79), respectively. There was no significant difference in mortality rates among the nonalbicans Candida spp. There was also no sex-related significant difference between mortality rates due to can- 
DISCUSSION
Nosocomial Candida infections are an important cause of morbidity and mortality in hospitalized patients. We carried out this retrospective study of Candida isolates in bloodstream infections for the years 2000 to 2009 to investigate changes in the distribution of causal species and their antifungal susceptibilities. We documented 270 Candida isolates from blood samples collected from patients with nosocomial bloodstream infections, and analyzed both the epidemiology and risk factors for candidemia.
Numerous investigators have reported that the frequency of severe infections caused by yeasts, particularly Candida spp., has increased dramatically in recent years (6, 8, 9, 21, 22) . Our retrospective study confirms that for 2000-2009, non-albicans Candida spp. were the most common cause of fungemia at our hospital. This could be due to the widespread reliance on fluconazole to treat these infections, concurrent with the increasing geographic distribution of non-albicans Candida spp.
During our study period, decisions to administer antifungal prophylaxis were based on the risk of IFI as determined by the IFI scoring system proposed by researchers at West Virginia University Hospital (23) . Fluconazole was the most routinely administered antifungal prophylactic for patients whose IFI score was À40 and who were thus at increased risk of developing invasive Candida infections. In particular, this included patients hospitalized in intensive care units or who had undergone major surgical interventions in the hospital. Unfortunately, the use of fluconazole allows for the preferential selection of species that are either resistant or less sensitive to it, such as C. krusei, C. glabrata, and C. tropicalis (24, 25) . Furthermore, many studies have implicated the use of azole antifungal agents, especially fluconazole, in the decreased isolation rate of C. albicans and the increased isolation rate of non-albicans Candida spp. (26, 27) .
Some research findings from Europe and the United
States have suggested that after C. albicans, the predominant species isolated from candidemia patients are C. glabrata and C. parapsilosis (11, 22, 28, 29) . Among the non-albicans Candida spp., C. parapsilosis is frequently associated with candidemia outbreaks in neonatal centers, burn units, and intensive care settings (30) (31) (32) . However, we found that C. tropicalis was the species with the second highest incidence, which is consistent with the findings of another study in China (33) . Previous studies from India have also demonstrated that C. tropicalis (35.3z) was a predominant Candida spp. in that country (21) . Therefore, the prevalence of infections due to a specific Candida (Table 3) . In this study, 86.7z of all Candida isolates were susceptible to fluconazole, and 94.8z of C. albicans was susceptible to fluconazole. C. glabrata had the highest fluconazole-resistance. Similarly, flucytosine susceptibility was common across all Candida spp. No significant difference in mortality rates was detected between initial treatment with fluconazole and amphotericin B; however, some patients who did not respond to fluconazole survived after shifting to amphotericin B. Amphotericin B also proved effective in some patients whose causal species was not susceptible to fluconazole, (susceptibility rated by in vitro testing). Therefore, amphotericin B may be the first choice for treatment of severe candidemia. This deduction requires supportive research.
The predisposing factors for the development of candidemia in our study were similar to those described previously (28, 29, 34, 35) . The presence of CVCs and previous administration of antibiotics were the principal conditions associated with increased risk. The majority of the infected patients had CVCs (87.8z), endotracheal intubation (70.7z), and/or total parenteral nutrition (45.6z). Antibiotics were used in all patients; on average, 6 ± 4.6 antibiotics were used for 20.6 ± 14.6 days prior to the development of candidemia.
The capacity of yeasts to attach to a wide range of inanimate surfaces (such as intravascular devices) and to form biofilms in glycosylated solutions appears to protect them from immune responses and antifungal agents. This may explain why Candida spp. infections are often associated with the use of CVCs and endotracheal intubation (36) . We consider the presence of CVCs not only a marker for severe illness, but also a predisposing factor for candidemia. Thus, CVC removal could reasonably be expected to decrease mortality rates due to these infections. However, CVCs were soon removed in most of our patients with candidemia, especially among those receiving total parenteral nutrition. In such cases, recolonization that takes place before the eradication of intravenous pathogens may be a problem. Prolonged hospital stays may also be an important risk factor for candidemia: for the 270 patients in our study: the median LOS prior to candidemia was 15 (range, 3-42) days.
Nosocomial bloodstream infections, including those caused by Candida, contribute to mortality rates in the United States (3, 37) . In our study, the mortality rate was 67z, which is a compelling reason for health teams to be aware of the potential risk factors for candidemia. While treatment outcomes may have improved with the availability of better therapies, mortality remains high largely due to delays in the delivery of appropriate therapy. This highlights the urgent need for more rapid and widely available diagnostic techniques. In addition, the lack of improvement in mortality rates could be related to a larger portion of severely ill patients in the current hospital environment. Prevention and control methods should be preemptively implemented.
In the present study, multivariate analysis revealed several independent adverse prognostic indicators (Table 4) . Endotracheal intubation, hypoproteinemia, and the presence of C. albicans were found to predict rapid mortality independently. In these patients, most indications for endotracheal intubation comprised severe pneumonia, acute respiratory distress syndrome, pulmonary embolism, or cardiogenic pulmonary edema. It is thus likely that in the context of mortality odds, endotracheal intubation is a marker of acute and severe respiratory and/or cardiovascular compromise. Most indications for hypoproteinemia in these patients comprised severe diseases such as liver cirrhosis, advanced stage hepatoma, and renal failure, which require liver or renal transplantation. In the context of mortality odds, the use of immunodepressive agents also was a risk factor of candidemia.
The main limitation of this study is that certain patient information was not available, and therefore we could not explore possible relevant interactions in a multiple analysis. These data included susceptibility to antifungal agents, malignancy, the use of immunodepressive agents and broad-spectrum antimicrobial agents, and LOS prior to candidemia.
In summary, this paper reports a retrospective analysis for the years 2000-2009 of 270 cases of candidemia at a university hospital in China. We found that the epidemiology and prognostic factors for candidemia have changed in recent years. Furthermore, the disease is associated with a high mortality rate that is likely to rise in the future with increases in the number of susceptible patients and as medical interventions become even more aggressive. Therefore, greater awareness of the risk factors, chance of mortality, and management is very important for clinicians. Despite the availability and extensive use of 7 potent antifungal agents, the following actions are urgently needed: (i) development of better methods for diagnosis of IFIs; (ii) reevaluation of the associated risk factors; (iii) creation of guidelines for the management of these infections; and (iv) the prudent but effective use of antifungal agents. Our research provides useful information and further insight into the epidemiology of candidemia, which should benefit the prevention and therapy for this disease in the future.
